- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03682770
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing double-blind placebo-controlled food challenge (DBPCFC) at visit 16.
Secondary objectives are:
- To assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the cumulative tolerated dose (log transformed) of peanut protein during a post up-dosing DBPCFC at visit 16
- To assess whether dupilumab as (indefinite [continuously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
- To assess whether dupilumab as (limited [previously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
- To evaluate the safety and tolerability of dupilumab as adjunct to AR101 compared to placebo
- To assess the effect of dupilumab (compared to placebo) as adjunct to AR101 on the change in peanut-specific Immunoglobulin E (sIgE), Immunoglobulin G (IgG), Immunoglobulin G4 (IgG4), and peanut-specific IgG4/IgE ratio
- To assess if dupilumab increases the tolerability of AR101 as measured by the daily symptoms (electronic diary [e-diary]) during the up-dosing phase
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Regeneron Investigational Site
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- Regeneron Investigational Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Regeneron Investigational Site
-
-
California
-
Los Angeles, California, United States, 90027
- Regeneron Investigational Site
-
Los Angeles, California, United States, 90095
- Regeneron Investigational Site
-
Mission Viejo, California, United States, 92691
- Regeneron Investigational Site
-
Mountain View, California, United States, 94040
- Regeneron Investigational Site
-
Rolling Hills Estates, California, United States, 90274
- Regeneron Investigational Site
-
-
Colorado
-
Denver, Colorado, United States, 80206
- Regeneron Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Regeneron Investigational Site
-
-
Florida
-
Tampa, Florida, United States, 33612
- Regeneron Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Regeneron Investigational Site
-
Marietta, Georgia, United States, 30144
- Regeneron Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Regeneron Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Regeneron Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Regeneron Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Regeneron Investigational Site
-
Ypsilanti, Michigan, United States, 48197
- Regeneron Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55402
- Regeneron Investigational Site
-
-
New Jersey
-
Ocean Township, New Jersey, United States, 07712
- Regeneron Investigational Site
-
-
New York
-
Great Neck, New York, United States, 11021
- Regeneron Investigational Site
-
New York, New York, United States, 10029
- Regeneron Investigational Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Regeneron Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Regeneron Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98115
- Regeneron Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Experience dose-limiting symptoms at or before the challenge dose of peanut protein on screening and not experiencing dose-limiting symptoms to placebo as defined in the protocol
- Serum Immunoglobulin E (IgE) to peanut of ≥10 kUA/L and/or a skin prick test (SPT) to peanut ≥8 mm compared to a negative control
- Participants/legal guardians must be trained on the proper use of the epinephrine autoinjector device to be allowed to enroll in the study
- Participants with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study
Key Exclusion Criteria:
- History of other chronic disease (other than asthma, Atopic Dermatitis (AD), or allergic rhinitis) requiring therapy (eg, heart disease, diabetes, hypertension) that would represent a risk to participant's health or safety in this study or ability to comply with study protocol
- History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock
- History of eosinophilic Gastrointestinal (GI) disease
Asthma at time of enrollment with any of the following:
- Forced Expiratory Volume 1 Second (FEV1) <80% of predicted or ratio of FEV1 to forced vital capacity (FEV1/FVC) <75% of predicted with or without controller medications
- Inhaled corticosteroids (ICS) dosing of daily fluticasone (or equivalent ICS based on NHLBI dosing chart)
- One hospitalization in the past year for asthma
- Emergency room visit for asthma within 6 months prior to screening
- Use of systemic corticosteroids within 2 months prior to screening
- Use of other forms of allergen immunotherapy or immunomodulatory therapy within 3 months prior to screening
- Use of any agents known or likely to interact with epinephrine (eg, beta-blockers, angiotensin converting enzyme-inhibitors, tri-cyclic antidepressants, or other drugs), within 3 weeks prior to screening
- Allergy to oat (placebo in DBPCFC)
Note: Other protocol Inclusion/Exclusion Criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dupilumab + AR101
Participant randomization of a ratio of 2 active dupilumab arms
|
Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
|
Experimental: placebo matching dupilumab + AR101
Participant randomization of a ratio of 1 placebo arm
|
AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
Placebo matching dupilumab is prepared in the same formulation without the addition of protein
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC) With 2044 mg (Cumulative) Peanut Protein at Visit 16 (Week 28 to 40)
Time Frame: At Visit 16 (Week 28 to 40)
|
Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions.
The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death.
the higher the grade, the more severe the allergic reaction.
Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction.
Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post up-dosing DBPCFC with 2044 mg (Cumulative) peanut protein at Visit 16 (Week 28 to 40) was reported.
Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).
|
At Visit 16 (Week 28 to 40)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 16 (Week 28 to 40) in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101
Time Frame: Baseline, Visit 16 (Week 28 to 40)
|
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 16 (Week 28 to 40) in participants treated with dupilumab plus AR101 vs placebo plus AR101 was reported.
Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 28 to Week 40).
|
Baseline, Visit 16 (Week 28 to 40)
|
Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Reached the 300 mg/Day Dose of AR101 by Visit 16 (Week 28 to 40)
Time Frame: At Visit 16 (Week 28 to 40)
|
Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who reached the 300 mg/day dose of AR101 by Visit 16 (Week 28 to 40) was reported.
Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).
|
At Visit 16 (Week 28 to 40)
|
Time From Randomization to the First Time When Participants Reached the 300 mg/Day Dose of AR101 During the Up-dosing Treatment Phase by Visit 16 (Week 28 to 40)
Time Frame: At Visit 16 (Week 28 to 40)
|
Time (in days) from randomization to the first time when participants reached the 300 mg/day dose of AR101 during the up-dosing treatment phase by Visit 16 (Week 28 to 40) was reported.
If participants did not reach the 300 mg/day dose of AR101 during the 28-week treatment period, they were censored at the date of their last visit during pre-AR101 dosing and AR101 up-dosing treatment period.
Analysis was performed using Kaplan-Meier Estimated method.
|
At Visit 16 (Week 28 to 40)
|
Percentage of Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)
Time Frame: At Visit 22 (Week 52 to 64)
|
Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions.
The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death.
the higher the grade, the more severe the allergic reaction.
Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction.
Percentage of participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported.
Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).
|
At Visit 22 (Week 52 to 64)
|
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101
Time Frame: Baseline, Visit 22 (Week 52 to 64)
|
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 was reported.
Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).
|
Baseline, Visit 22 (Week 52 to 64)
|
Percentage of Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)
Time Frame: At Visit 22 (Week 52 to 64)
|
Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions.
The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death.
the higher the grade, the more severe the allergic reaction.
Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction.
Percentage of participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 who "pass" a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported.
Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).
|
At Visit 22 (Week 52 to 64)
|
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101
Time Frame: Baseline, Visit 22 (Week 52 to 64)
|
Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 was reported.
Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).
|
Baseline, Visit 22 (Week 52 to 64)
|
Percent Change From Baseline in Peanut-specific IgE in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 16 (Week 28 to 40)
Time Frame: Baseline up to Visit 16 (Weeks 28 to 40)
|
Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 16 (Week 28 to 40) was reported.
Analysis was performed using Last observation carried forward (LOCF) method.
Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).
|
Baseline up to Visit 16 (Weeks 28 to 40)
|
Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 22 (Week 52 to 64)
Time Frame: Baseline up to Visit 22 (Week 52 to 64)
|
Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 22 (Week 52 to 64) was reported.
Analysis was performed using LOCF method.
Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).
|
Baseline up to Visit 22 (Week 52 to 64)
|
Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 25 (Weeks 64 to 76)
Time Frame: Baseline up to Visit 25 (Weeks 64 to 76)
|
Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 25 (Week 64 to 76) was reported.
Analysis was performed using LOCF method.
Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 64 to Week 76).
|
Baseline up to Visit 25 (Weeks 64 to 76)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R668-ALG-16114
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peanut Allergy
-
Rima RachidUniversity of MinnesotaRecruitingPeanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, PeanutUnited States
-
Scripps HealthThe Scripps Research InstituteWithdrawnFood Allergy PeanutUnited States
-
Novartis PharmaceuticalsTerminatedAllergy, PeanutUnited States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
-
University of ManitobaThe Hospital for Sick Children; University of British Columbia; McGill UniversityEnrolling by invitationAllergy to Peanut
-
Imperial College LondonUniversity of Sydney; National Institute for Health Research, United KingdomCompletedIgE Mediated Peanut AllergyUnited Kingdom
-
King's College LondonCharite University, Berlin, Germany; University Hospital, Bonn; Institut Curie; Levantine UKNot yet recruitingAllergy;Food | Food Allergy Peanut | Pathways and Sources of Exposure
-
Imperial College LondonUniversity College CorkActive, not recruitingPeanut Hypersensitivity | IgE Mediated Peanut AllergyUnited Kingdom
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.Active, not recruitingPeanut Allergy | Multi-food AllergyUnited States
-
Scott SichererNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPeanut Allergy | Food AllergyUnited States
Clinical Trials on Dupilumab
-
Brigham and Women's HospitalRegeneron PharmaceuticalsRecruiting
-
Akron Children's HospitalRegeneron Pharmaceuticals; Ohio State UniversityNot yet recruiting
-
University of MichiganRegeneron PharmaceuticalsRecruiting
-
Northwestern UniversityRecruitingSkin DiseasesUnited States
-
University of California, San FranciscoRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAsthma; EosinophilicSpain
-
Montefiore Medical CenterRegeneron PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolypsUnited States
-
Johns Hopkins UniversityDoris Duke Charitable FoundationRecruiting
-
University of RochesterNot yet recruiting